Affinity Asset Advisors LLC Has $4.74 Million Stock Position in Perspective Therapeutics, Inc. $CATX

Key Points

• Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics, Inc. by 71.1%, owning 2,224,196 shares valued at approximately $4.74 million after acquiring additional shares in the first quarter.
• Analyst ratings show a generally positive outlook for Perspective Therapeutics, with a consensus rating of "Buy" and a price target averaging $12.56.
• Perspective Therapeutics specializes in precision-targeted alpha therapies for oncology, currently advancing its treatments through Phase 1/2a clinical trials for specific cancer types.

Affinity Asset Advisors LLC lifted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 71.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,224,196 shares of the company's stock after purchasing an additional 924,196 shares during the period. Affinity Asset Advisors LLC owned approximately 3.00% of Perspective Therapeutics worth $4,738,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CATX. ProShare Advisors LLC increased its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after purchasing an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $51,000. Corton Capital Inc. acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $61,000. Wexford Capital LP acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $64,000. Finally, Virtus ETF Advisers LLC raised its stake in Perspective Therapeutics by 157.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 20,487 shares of the company's stock worth $65,000 after purchasing an additional 12,542 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CATX has been the subject of several analyst reports. Truist Financial dropped their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Wedbush restated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. B. Riley restated a "buy" rating and issued a $12.00 target price (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $12.56.

Perspective Therapeutics Trading Down 0.6%

Shares of Perspective Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $3.36. 456,073 shares of the company traded hands, compared to its average volume of 927,790. The firm's fifty day moving average price is $3.79 and its 200-day moving average price is $2.97. Perspective Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $16.31.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.